The global market for Secondary Antibodies was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Secondary Antibodies is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Secondary Antibodies is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Secondary Antibodies include Thermo Fisher Scientific (US), Jackson ImmunoResearch Laboratories (US), BD Biosciences (US), Santa Cruz Biotechnology (US), GE Healthcare (US), Sigma-Aldrich (US), Dako (US), LI-COR Biosciences (US), SouthernBiotech (US), Vector Laboratories (US), etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Secondary Antibodies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Secondary Antibodies.
The Secondary Antibodies market size, estimations, and forecasts are provided in terms of sales volume (MT) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Secondary Antibodies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Secondary Antibodies manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Thermo Fisher Scientific (US)
Jackson ImmunoResearch Laboratories (US)
BD Biosciences (US)
Santa Cruz Biotechnology (US)
GE Healthcare (US)
Sigma-Aldrich (US)
Dako (US)
LI-COR Biosciences (US)
SouthernBiotech (US)
Vector Laboratories (US)
Bio-Rad (US)
eBioscience (US)
Cell Signaling Technology (US)
Dianova (Germany)
Abcam (UK)
EMD Millipore (US)
R&D Systems (US)
Rockland Immunochemicals (US)
Bethyl (US)
Kirkegaard & Perry Laboratories (US)
BioLegend (US)
Abbexa (UK)
Biorbyt (UK)
Acris Antibodies (Germany)
BioLogo (Germany)
Sino Biological (China)
Segment by Type
Men'
Animals'
Segment by Application
ELISA (Including Many HIV Tests)
Western Blot
Immunostaining
Immunohistochemistry
Immunocytochemistry
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Secondary Antibodies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Secondary Antibodies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Secondary Antibodies Market Overview
1.1 Product Definition
1.2 Secondary Antibodies by Type
1.2.1 Global Secondary Antibodies Market Value Comparison by Type (2024 VS 2031)
1.2.2 Men'
1.2.3 Animals'
1.3 Secondary Antibodies by Application
1.3.1 Global Secondary Antibodies Market Value by Application (2024 VS 2031)
1.3.2 ELISA (Including Many HIV Tests)
1.3.3 Western Blot
1.3.4 Immunostaining
1.3.5 Immunohistochemistry
1.3.6 Immunocytochemistry
1.4 Global Secondary Antibodies Market Size Estimates and Forecasts
1.4.1 Global Secondary Antibodies Revenue 2020-2031
1.4.2 Global Secondary Antibodies Sales 2020-2031
1.4.3 Global Secondary Antibodies Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Secondary Antibodies Market Competition by Manufacturers
2.1 Global Secondary Antibodies Sales Market Share by Manufacturers (2020-2025)
2.2 Global Secondary Antibodies Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Secondary Antibodies Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Secondary Antibodies, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Secondary Antibodies, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Secondary Antibodies, Product Type & Application
2.7 Global Key Manufacturers of Secondary Antibodies, Date of Enter into This Industry
2.8 Global Secondary Antibodies Market Competitive Situation and Trends
2.8.1 Global Secondary Antibodies Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Secondary Antibodies Players Market Share by Revenue
2.8.3 Global Secondary Antibodies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Secondary Antibodies Market Scenario by Region
3.1 Global Secondary Antibodies Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Secondary Antibodies Sales by Region: 2020-2031
3.2.1 Global Secondary Antibodies Sales by Region: 2020-2025
3.2.2 Global Secondary Antibodies Sales by Region: 2026-2031
3.3 Global Secondary Antibodies Revenue by Region: 2020-2031
3.3.1 Global Secondary Antibodies Revenue by Region: 2020-2025
3.3.2 Global Secondary Antibodies Revenue by Region: 2026-2031
3.4 North America Secondary Antibodies Market Facts & Figures by Country
3.4.1 North America Secondary Antibodies Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Secondary Antibodies Sales by Country (2020-2031)
3.4.3 North America Secondary Antibodies Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Secondary Antibodies Market Facts & Figures by Country
3.5.1 Europe Secondary Antibodies Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Secondary Antibodies Sales by Country (2020-2031)
3.5.3 Europe Secondary Antibodies Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Secondary Antibodies Market Facts & Figures by Region
3.6.1 Asia Pacific Secondary Antibodies Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Secondary Antibodies Sales by Region (2020-2031)
3.6.3 Asia Pacific Secondary Antibodies Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Secondary Antibodies Market Facts & Figures by Country
3.7.1 Latin America Secondary Antibodies Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Secondary Antibodies Sales by Country (2020-2031)
3.7.3 Latin America Secondary Antibodies Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Secondary Antibodies Market Facts & Figures by Country
3.8.1 Middle East and Africa Secondary Antibodies Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Secondary Antibodies Sales by Country (2020-2031)
3.8.3 Middle East and Africa Secondary Antibodies Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Secondary Antibodies Sales by Type (2020-2031)
4.1.1 Global Secondary Antibodies Sales by Type (2020-2025)
4.1.2 Global Secondary Antibodies Sales by Type (2026-2031)
4.1.3 Global Secondary Antibodies Sales Market Share by Type (2020-2031)
4.2 Global Secondary Antibodies Revenue by Type (2020-2031)
4.2.1 Global Secondary Antibodies Revenue by Type (2020-2025)
4.2.2 Global Secondary Antibodies Revenue by Type (2026-2031)
4.2.3 Global Secondary Antibodies Revenue Market Share by Type (2020-2031)
4.3 Global Secondary Antibodies Price by Type (2020-2031)
5 Segment by Application
5.1 Global Secondary Antibodies Sales by Application (2020-2031)
5.1.1 Global Secondary Antibodies Sales by Application (2020-2025)
5.1.2 Global Secondary Antibodies Sales by Application (2026-2031)
5.1.3 Global Secondary Antibodies Sales Market Share by Application (2020-2031)
5.2 Global Secondary Antibodies Revenue by Application (2020-2031)
5.2.1 Global Secondary Antibodies Revenue by Application (2020-2025)
5.2.2 Global Secondary Antibodies Revenue by Application (2026-2031)
5.2.3 Global Secondary Antibodies Revenue Market Share by Application (2020-2031)
5.3 Global Secondary Antibodies Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Thermo Fisher Scientific (US)
6.1.1 Thermo Fisher Scientific (US) Company Information
6.1.2 Thermo Fisher Scientific (US) Description and Business Overview
6.1.3 Thermo Fisher Scientific (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Thermo Fisher Scientific (US) Secondary Antibodies Product Portfolio
6.1.5 Thermo Fisher Scientific (US) Recent Developments/Updates
6.2 Jackson ImmunoResearch Laboratories (US)
6.2.1 Jackson ImmunoResearch Laboratories (US) Company Information
6.2.2 Jackson ImmunoResearch Laboratories (US) Description and Business Overview
6.2.3 Jackson ImmunoResearch Laboratories (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Jackson ImmunoResearch Laboratories (US) Secondary Antibodies Product Portfolio
6.2.5 Jackson ImmunoResearch Laboratories (US) Recent Developments/Updates
6.3 BD Biosciences (US)
6.3.1 BD Biosciences (US) Company Information
6.3.2 BD Biosciences (US) Description and Business Overview
6.3.3 BD Biosciences (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.3.4 BD Biosciences (US) Secondary Antibodies Product Portfolio
6.3.5 BD Biosciences (US) Recent Developments/Updates
6.4 Santa Cruz Biotechnology (US)
6.4.1 Santa Cruz Biotechnology (US) Company Information
6.4.2 Santa Cruz Biotechnology (US) Description and Business Overview
6.4.3 Santa Cruz Biotechnology (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Santa Cruz Biotechnology (US) Secondary Antibodies Product Portfolio
6.4.5 Santa Cruz Biotechnology (US) Recent Developments/Updates
6.5 GE Healthcare (US)
6.5.1 GE Healthcare (US) Company Information
6.5.2 GE Healthcare (US) Description and Business Overview
6.5.3 GE Healthcare (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.5.4 GE Healthcare (US) Secondary Antibodies Product Portfolio
6.5.5 GE Healthcare (US) Recent Developments/Updates
6.6 Sigma-Aldrich (US)
6.6.1 Sigma-Aldrich (US) Company Information
6.6.2 Sigma-Aldrich (US) Description and Business Overview
6.6.3 Sigma-Aldrich (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Sigma-Aldrich (US) Secondary Antibodies Product Portfolio
6.6.5 Sigma-Aldrich (US) Recent Developments/Updates
6.7 Dako (US)
6.7.1 Dako (US) Company Information
6.7.2 Dako (US) Description and Business Overview
6.7.3 Dako (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Dako (US) Secondary Antibodies Product Portfolio
6.7.5 Dako (US) Recent Developments/Updates
6.8 LI-COR Biosciences (US)
6.8.1 LI-COR Biosciences (US) Company Information
6.8.2 LI-COR Biosciences (US) Description and Business Overview
6.8.3 LI-COR Biosciences (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.8.4 LI-COR Biosciences (US) Secondary Antibodies Product Portfolio
6.8.5 LI-COR Biosciences (US) Recent Developments/Updates
6.9 SouthernBiotech (US)
6.9.1 SouthernBiotech (US) Company Information
6.9.2 SouthernBiotech (US) Description and Business Overview
6.9.3 SouthernBiotech (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.9.4 SouthernBiotech (US) Secondary Antibodies Product Portfolio
6.9.5 SouthernBiotech (US) Recent Developments/Updates
6.10 Vector Laboratories (US)
6.10.1 Vector Laboratories (US) Company Information
6.10.2 Vector Laboratories (US) Description and Business Overview
6.10.3 Vector Laboratories (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Vector Laboratories (US) Secondary Antibodies Product Portfolio
6.10.5 Vector Laboratories (US) Recent Developments/Updates
6.11 Bio-Rad (US)
6.11.1 Bio-Rad (US) Company Information
6.11.2 Bio-Rad (US) Description and Business Overview
6.11.3 Bio-Rad (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Bio-Rad (US) Secondary Antibodies Product Portfolio
6.11.5 Bio-Rad (US) Recent Developments/Updates
6.12 eBioscience (US)
6.12.1 eBioscience (US) Company Information
6.12.2 eBioscience (US) Description and Business Overview
6.12.3 eBioscience (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.12.4 eBioscience (US) Secondary Antibodies Product Portfolio
6.12.5 eBioscience (US) Recent Developments/Updates
6.13 Cell Signaling Technology (US)
6.13.1 Cell Signaling Technology (US) Company Information
6.13.2 Cell Signaling Technology (US) Description and Business Overview
6.13.3 Cell Signaling Technology (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Cell Signaling Technology (US) Secondary Antibodies Product Portfolio
6.13.5 Cell Signaling Technology (US) Recent Developments/Updates
6.14 Dianova (Germany)
6.14.1 Dianova (Germany) Company Information
6.14.2 Dianova (Germany) Description and Business Overview
6.14.3 Dianova (Germany) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Dianova (Germany) Secondary Antibodies Product Portfolio
6.14.5 Dianova (Germany) Recent Developments/Updates
6.15 Abcam (UK)
6.15.1 Abcam (UK) Company Information
6.15.2 Abcam (UK) Description and Business Overview
6.15.3 Abcam (UK) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Abcam (UK) Secondary Antibodies Product Portfolio
6.15.5 Abcam (UK) Recent Developments/Updates
6.16 EMD Millipore (US)
6.16.1 EMD Millipore (US) Company Information
6.16.2 EMD Millipore (US) Description and Business Overview
6.16.3 EMD Millipore (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.16.4 EMD Millipore (US) Secondary Antibodies Product Portfolio
6.16.5 EMD Millipore (US) Recent Developments/Updates
6.17 R&D Systems (US)
6.17.1 R&D Systems (US) Company Information
6.17.2 R&D Systems (US) Description and Business Overview
6.17.3 R&D Systems (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.17.4 R&D Systems (US) Secondary Antibodies Product Portfolio
6.17.5 R&D Systems (US) Recent Developments/Updates
6.18 Rockland Immunochemicals (US)
6.18.1 Rockland Immunochemicals (US) Company Information
6.18.2 Rockland Immunochemicals (US) Description and Business Overview
6.18.3 Rockland Immunochemicals (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Rockland Immunochemicals (US) Secondary Antibodies Product Portfolio
6.18.5 Rockland Immunochemicals (US) Recent Developments/Updates
6.19 Bethyl (US)
6.19.1 Bethyl (US) Company Information
6.19.2 Bethyl (US) Description and Business Overview
6.19.3 Bethyl (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Bethyl (US) Secondary Antibodies Product Portfolio
6.19.5 Bethyl (US) Recent Developments/Updates
6.20 Kirkegaard & Perry Laboratories (US)
6.20.1 Kirkegaard & Perry Laboratories (US) Company Information
6.20.2 Kirkegaard & Perry Laboratories (US) Description and Business Overview
6.20.3 Kirkegaard & Perry Laboratories (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.20.4 Kirkegaard & Perry Laboratories (US) Secondary Antibodies Product Portfolio
6.20.5 Kirkegaard & Perry Laboratories (US) Recent Developments/Updates
6.21 BioLegend (US)
6.21.1 BioLegend (US) Company Information
6.21.2 BioLegend (US) Description and Business Overview
6.21.3 BioLegend (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.21.4 BioLegend (US) Secondary Antibodies Product Portfolio
6.21.5 BioLegend (US) Recent Developments/Updates
6.22 Abbexa (UK)
6.22.1 Abbexa (UK) Company Information
6.22.2 Abbexa (UK) Description and Business Overview
6.22.3 Abbexa (UK) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.22.4 Abbexa (UK) Secondary Antibodies Product Portfolio
6.22.5 Abbexa (UK) Recent Developments/Updates
6.23 Biorbyt (UK)
6.23.1 Biorbyt (UK) Company Information
6.23.2 Biorbyt (UK) Description and Business Overview
6.23.3 Biorbyt (UK) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.23.4 Biorbyt (UK) Secondary Antibodies Product Portfolio
6.23.5 Biorbyt (UK) Recent Developments/Updates
6.24 Acris Antibodies (Germany)
6.24.1 Acris Antibodies (Germany) Company Information
6.24.2 Acris Antibodies (Germany) Description and Business Overview
6.24.3 Acris Antibodies (Germany) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.24.4 Acris Antibodies (Germany) Secondary Antibodies Product Portfolio
6.24.5 Acris Antibodies (Germany) Recent Developments/Updates
6.25 BioLogo (Germany)
6.25.1 BioLogo (Germany) Company Information
6.25.2 BioLogo (Germany) Description and Business Overview
6.25.3 BioLogo (Germany) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.25.4 BioLogo (Germany) Secondary Antibodies Product Portfolio
6.25.5 BioLogo (Germany) Recent Developments/Updates
6.26 Sino Biological (China)
6.26.1 Sino Biological (China) Company Information
6.26.2 Sino Biological (China) Description and Business Overview
6.26.3 Sino Biological (China) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.26.4 Sino Biological (China) Secondary Antibodies Product Portfolio
6.26.5 Sino Biological (China) Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Secondary Antibodies Industry Chain Analysis
7.2 Secondary Antibodies Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Secondary Antibodies Production Mode & Process Analysis
7.4 Secondary Antibodies Sales and Marketing
7.4.1 Secondary Antibodies Sales Channels
7.4.2 Secondary Antibodies Distributors
7.5 Secondary Antibodies Customer Analysis
8 Secondary Antibodies Market Dynamics
8.1 Secondary Antibodies Industry Trends
8.2 Secondary Antibodies Market Drivers
8.3 Secondary Antibodies Market Challenges
8.4 Secondary Antibodies Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Thermo Fisher Scientific (US)
Jackson ImmunoResearch Laboratories (US)
BD Biosciences (US)
Santa Cruz Biotechnology (US)
GE Healthcare (US)
Sigma-Aldrich (US)
Dako (US)
LI-COR Biosciences (US)
SouthernBiotech (US)
Vector Laboratories (US)
Bio-Rad (US)
eBioscience (US)
Cell Signaling Technology (US)
Dianova (Germany)
Abcam (UK)
EMD Millipore (US)
R&D Systems (US)
Rockland Immunochemicals (US)
Bethyl (US)
Kirkegaard & Perry Laboratories (US)
BioLegend (US)
Abbexa (UK)
Biorbyt (UK)
Acris Antibodies (Germany)
BioLogo (Germany)
Sino Biological (China)
听
听
*If Applicable.